Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real‐world multicentre UK retrospective analysis
Sign Up to like & getrecommendations! Published in 2023 at "British Journal of Haematology"
DOI: 10.1111/bjh.18703
Abstract: Daratumumab, bortezomib and dexamethasone (DVd) is approved for patients with relapsed multiple myeloma following the CASTOR phase 3 clinical trial. This retrospective multicentre analysis assesses the overall response rate (ORR) and progression‐free survival (PFS) in… read more here.
Keywords: bortezomib; daratumumab bortezomib; multiple myeloma; first relapse ... See more keywords